To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma. Patients in relapse after first-, second-, or third-line therapy received 40 mg m-2 intravenous (i.v.) cisplatin, 1000 mg m -2 i.v. gemcitabine, and 2500 mg m-2 i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan therapy was repeated every 5 weeks until progression of disease occurred. A maximum of 11 CGT cycles (mean, two cycles) was administered per patient. Four patients (4%) showed a partial response; 15 (17%) patients had stable disease; and 72 (79%) patients progressed upon first re-evaluation. Overall survival of all 91 patients was 6 months (2-year survival rate, 7%). Patients with partial remission or stable disease exhibited a median overall survival of 11 months (2-year survival rate, 36%), while patients with disease progression upon first re-evaluation had a median overall survival of 5 months (2-year survival rate, 0%). Treatment with CGT was efficient in one-fifth of the pretreated relapsed stage IV melanoma patients achieving disease stabilisation or partial remission with prolonged but limited survival. © 2007 Cancer Research UK.
CITATION STYLE
Atzpodien, J., Terfloth, K., Fluck, M., & Reitz, M. (2007). Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. British Journal of Cancer, 97(10), 1329–1332. https://doi.org/10.1038/sj.bjc.6604045
Mendeley helps you to discover research relevant for your work.